<DOC>
	<DOC>NCT00694707</DOC>
	<brief_summary>This is an study to evaluate the safety, efficacy, and tolerability of RGH-188 relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.</brief_summary>
	<brief_title>Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Male or female 18 to 60 years of age meeting DSMIV criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type) based on the SCID having a total PANSS score greater than or equal to 80 and less than or equal to 120 Patients with a schizophrenia diagnosis for a minimum of 1 year. Patients who exhibit abnormalities on Physical Examination, have abnormal vital signs, ECG, or clinical laboratory values. Patients experiencing first episode of psychosis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>